Skip to main content
PharmaMar announces that its second most advanced marine-derived antitumor agent, Aplidin, has commenced Phase II clinical trials in both prostate and bladder cancers.

In the Pipeline

May 1, 2005

In The Pipeline

  • PharmaMar announces that its second most advanced marine-derived antitumor agent, Aplidin, has commenced Phase II clinical trials in both prostate and bladder cancers.
  • TheraQuest Biosciences has announced that the FDA Office of Orphan Products Development has granted orphan drug designation for TQ-1017, the company’s abuse deterrent once-daily extended-release tramadol for the treatment of HIV-associated neuropathy.
  • Icagen has initiated enrollment in its pivotal Phase III trial of ICA-17043 for the treatment of sickle cell disease.
  • Human Genome Sciences has completed the enrollment and initial dosing of patients in a Phase II clinical trial of mapatumumab (HGS-ETR1) in patients with advanced colorectal cancer.
  • Oncolytics Biotech has received clearance from the FDA to begin a Phase I/II clinical trial to investigate the use of Reolysin, its proprietary formulation of the human reovirus, to treat patients with recurrent malignant gliomas.